All Oncology News

Patients with pancreatic lesions have been treated with endoscopy-guided microwave therapy according to researchers at WVU Medicine.

Epcoritamab displayed a significant PFS benefit vs chemotherapy in relapsed/refractory DLBCL.

The EMA has validated a Type II variation application for trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive metastatic breast cancer.

Toripalimab and chidamide demonstrated particularly notable efficacy outcomes in well-differentiated liposarcoma and dedifferentiated liposarcoma.

Xiuning Le, MD, PhD, discusses the FDA approval of sevabertinib for pretreated, advanced, nonsquamous NSCLC with tumors harboring HER2 TKD mutations.

Ianalumab plus ibrutinib showed promising efficacy and uMRD rates with manageable safety in a phase 1b study of patients with CLL.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

Lorenzo Falchi, MD, discusses the FDA approval of epcoritamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

Micvotabart pelidotin produced early activity in head and neck squamous cell carcinoma as monotherapy and in combination with pembrolizumab.

Guilherme Nader-Marta, MD, and Erica L. Mayer, MD, MPH, discusses innovative treatments for HR-positive, HER2-negative metastatic breast cancer.

Scott M. Haake, MD, PhD, discusses how RNAseq-defined clusters could guide treatment selection in metastatic ccRCC, based on data from the OPTIC trial.

Anamorelin plus chemotherapy was well tolerated and potentially associated with efficacy in metastatic urothelial carcinoma.

Treatment with nogapendekin alfa inbakicept plus BCG prolonged duration of complete response compared with BCG alone in patients with BCG-naive NMIBC.

Treatment with an allogeneic CD19-directed CAR natural killer–cell therapy led to an ongoing complete response at 15 months in Waldenstrom lymphoma.

Mayo Clinic’s Department of Radiation Oncology has developed an AI monitoring tool to support clinicians in monitoring for prostate cancer recurrence.

Elena Elimova, MD, discusses findings for zanidatamab chemotherapy with/without tislelizumab in advanced HER2-positive gastroesophageal adenocarcinoma.

ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.

Treatment with pembrolizumab after GI-6207 therapy did not generate therapeutic responses in patients with recurrent/metastatic medullary thyroid cancer.

Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The AACN's Beacon Award for Excellence has been awarded to Roswell Park Comprehensive Cancer Center's Intensive Care Unit.

The autologous tumor-cell immunotherapy improved OS and RFS vs placebo in patients who achieved a CR after undergoing surgery and frontline chemotherapy.

Teclistamab monotherapy significantly improved PFS and OS vs standard-of-care therapy in relapsed/refractory multiple myeloma as early as the second line.

Yue Wei, PhD, discussed the role of HMAs in platelet response in MDS and the clinical relevance of using a mouse model to investigate this approach.

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

SCIB1/iSCIB1+ plus ipilimumab and nivolumab displayed T-cell responses in treatment-naive, unresectable melanoma.

Updated data from the GOBLET trial show pelareorep plus atezolizumab achieved a 29% ORR with durable responses in heavily pretreated SCAC.

Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.

Mark A. Socinski, MD, and Martin F. Dietrich, MD, PhD, discuss molecular testing methodologies for NSCLC.

Nogapendekin alfa inbakicept plus an immune checkpoint inhibitor generated absolute lymphocyte count increases in non–small cell lung cancer.